SCHEMBL4008191

SCHEMBL4008191

Cc1cc2[nH]nc(-c3ccccc3)c2cc1[N+](=O)[O-]

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.62
MAPT P10636 1/20 0.62
LRRK2 Q5S007 2/20 0.49
AURKB Q96GD4 2/20 0.47
MAP2K4 P45985 2/20 0.47
DCLK1 O15075 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
CHEK2 O96017 1/20 0.47
CSF1R P07333 1/20 0.47
FER P16591 1/20 0.47
CDK2 P24941 1/20 0.47
MARK3 P27448 1/20 0.47
FLT4 P35916 1/20 0.47
FLT3 P36888 1/20 0.47
MAPK9 P45984 1/20 0.47
CSNK1D P48730 1/20 0.47
CLK2 P49760 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CSNK1G2 P78368 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18216944 0.79 ADORA2A (0.45) MAPTLRRK2AURKBKDM4EALDH1A1
SCHEMBL1513036 0.77 MAPT (0.78) HPGDMAPTMAP2K4CDK2KDM4E
SCHEMBL4007995 0.77 MAPT (1.00) HPGDMAPTLRRK2AURKBDCLK1
SCHEMBL6850338 0.77 MAPT (0.54) HPGDMAPTLRRK2AURKBMAP2K4
SCHEMBL1199907 0.76 CYP1A2 (0.41) MAPTAURKBKDM4EALDH1A1GAA
SCHEMBL1028170 0.76 TSHR (0.38) MAPTAURKBKDM4EALDH1A1GAA
SCHEMBL5377226 0.74 MAPT (0.94) HPGDMAPTLRRK2AURKBDCLK1
SCHEMBL10151125 0.74 ADORA2A (0.44) HPGDMAPTLRRK2KDM4EALDH1A1
SCHEMBL4007672 0.74 CDK2 (0.57) HPGDMAPTAURKBMAP2K4DCLK1
SCHEMBL16862707 0.74 MAPK10 (0.67) HPGDMAPTLRRK2AURKBMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HPGD 1246/4885MAPT 2426/4885LRRK2 527/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HPGD 1303/4885MAPT 3070/4885LRRK2 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.